On July 10, seven departments including the Ministry of Agriculture and Rural Affairs jointly held a meeting in Beijing to deploy and initiate a comprehensive campaign to further regulate the production, operation, and use of pesticides and veterinary drugs. The Supreme People's Court, the Supreme People's Procuratorate, and the Ministry of Public Security all participated—the high level and strong measures of this campaign send a clear signal: the veterinary drug industry is now under serious scrutin

9 months, zero tolerance for the entire chain

      The comprehensive rectification action will be launched in July 2026 and will end by the end of March 2027, focusing on the full chain rectification of the production, operation, online sales, and use of banned and restricted pesticides and veterinary drugs. Strengthen efforts to crack down on the source, end dens, and investigate major cases, and resolutely cut off the illegal chain. Industry regulation continues to intensify, and compliance management has shifted from a "multiple-choice question" to a "mandatory question".

Compliance is Enhe's bottom line

      Industry rectification continues to intensify, and compliant operation is the long-term solution. Since its establishment in 2008, Enhe Pharmaceutical has always regarded compliance and legality as the bottom line and lifeline of its business operations. Legitimacy is a prerequisite for the research and development process. Relying on the core R&D engine of Zhuoxin Research Institute, Enhe insists on controlling raw materials from the source, and all R&D projects strictly comply with laws and regulations such as the "Regulations on the Administration of Veterinary Drugs". Langxin Biotechnology focuses on the research and production of animal health products and feed additives, holding multiple patents and qualifications. In 2025, it was officially approved as a doctoral innovation station in Shanxi Province. Three companies collaborate and link together to build a complete animal protection industry ecosystem from scientific research to production.

      Compliance is the standard in the production process. Enhe has passed the new version of animal medicine GMP certification, high-tech enterprise certification, and ISO9001 quality management system certification. It has a production workshop of 10000 square meters, multiple animal medicine production lines, and more than 180 approval numbers. Each batch of products strictly follows national standards and internal quality control standards from raw material entry to finished product delivery, ensuring batch traceability and item verifiability.

      Compliance with the law is the bottom line in the sales process. In the current situation where the regulation of online sales of veterinary drugs is increasingly tightened, Enhe always adheres to compliant channels and compliant promotion, and does not engage in false advertising or sell "three no" products. Veterinary prescription drugs are strictly sold based on prescriptions, and all business activities are carried out within the framework of laws and regulations

      In the future, Enhe will continue to produce and operate in compliance with national veterinary drug management laws and regulations, strictly abide by various rules and regulations, actively adapt to policy requirements such as the upgrade of the new version of veterinary drug standards, continue to increase research and development investment, and drive product upgrades with technological innovation. At the same time, Enhe will continue to uphold the corporate mission of "Jin merchants being kind and inheriting good formulas, Jin merchants being Enhe and strategic partners", collaborate with Langxin Biotechnology and Zhuoxin Research Institute, guided by the core values of benevolence, kindness, diligence, learning, and harmony, and work together with all parties to seek industrial development and continuously empower the high-quality development of the animal husbandry and animal protection industry.